Amylyx Pharmaceuticals, Inc. (AMLX)

$14.22

+0.06

(+0.42%)

Market is closed - opens 8 PM, 04 Dec 2023

Insights on Amylyx Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 285.0K → 102.69M (in $), with an average increase of 43.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 22.07M → 20.89M (in $), with an average decrease of 5.4% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 137.6%

Performance

  • $13.42
    $14.29
    $14.22
    downward going graph

    5.63%

    Downside

    Day's Volatility :6.06%

    Upside

    0.46%

    downward going graph
  • $11.82
    $41.93
    $14.22
    downward going graph

    16.88%

    Downside

    52 Weeks Volatility :71.81%

    Upside

    66.09%

    downward going graph

Returns

PeriodAmylyx Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-31.1%
-1.3%
0.0%
6 Months
-43.53%
1.2%
0.0%
1 Year
-63.75%
-5.7%
-6.5%
3 Years
-21.31%
18.2%
-3.8%

Highlights

Market Capitalization
853.4M
Book Value
$6.2
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.01
PE Ratio
1264.0
Wall Street Target Price
39.4
Profit Margin
0.62%
Operating Margin TTM
18.23%
Return On Assets TTM
-1.49%
Return On Equity TTM
0.65%
Revenue TTM
294.2M
Revenue Per Share TTM
4.41
Quarterly Revenue Growth YOY
29666.1%
Gross Profit TTM
-74.2M
EBITDA
-6.8M
Diluted Eps TTM
0.01
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.86
EPS Estimate Next Year
1.35
EPS Estimate Current Quarter
0.44
EPS Estimate Next Quarter
0.54

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Amylyx Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 177.07%

Current $14.22
Target $39.40

Technicals Summary

Sell

Neutral

Buy

Amylyx Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
-21.09%
-43.53%
-63.75%
-21.31%
-21.31%
Moderna, Inc.
Moderna, Inc.
12.07%
-38.83%
-56.22%
-44.17%
329.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.48%
10.12%
6.32%
61.32%
112.97%
Novo Nordisk A/s
Novo Nordisk A/s
-0.53%
27.78%
58.23%
194.69%
336.14%
Seagen, Inc.
Seagen, Inc.
-0.96%
8.88%
73.78%
20.15%
232.63%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.74%
5.21%
9.27%
54.9%
90.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
1264.0
1264.0
NA
0.86
0.01
-0.01
0.0
6.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc.
Buy
$853.4M
-21.31%
1264.0
0.62%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
329.19%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
112.97%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
336.14%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
232.63%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
90.18%
26.52
35.94%

Institutional Holdings

  • Vanguard Group Inc

    7.48%
  • BlackRock Inc

    5.19%
  • Viking Global Investors LP

    4.39%
  • Perceptive Advisors LLC

    3.98%
  • Stonepine Capital Management Llc

    3.73%
  • Boxer Capital LLC

    3.09%

Company Information

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.

Organization
Amylyx Pharmaceuticals, Inc.
Employees
374
CEO
Mr. Joshua B. Cohen
Industry
Services

FAQs